fashion -WSS

fashion

author：hotspot 2025-10-02 17:27:22 - browse：9182

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Second House panel advances two

leisure time

WSS

Bird flu: Don't repeat Covid's 'health versus the economy' framing

When prostate cancer spreads, where it goes matters

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Readers respond to H5N1 and livestock movements, and more

The real point of Kenneth Smith’s execution by nitrogen gas

A $475,000 price tag for a new cancer drug: crazy or meh?

leisure time

fashion

entertainment

How one medical school became remarkably diverse

Do digital therapeutics have a future in medicine?

Activists slam private health insurers over coverage restrictions

A $475,000 price tag for a new cancer drug: crazy or meh?

Drug repurposing or repositioning? The language matters

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Alkermes shareholders re

Congressmen charge Covid hearing ‘could have been an email’

Medicare details structure of new drug price negotiation program

Even great ERs can’t make up for American health disparities

Wikipedia

HIV vaccine remains elusive. Immunologists keep trying new ideas

Juul spent big to court Black leaders to promote its e

Do digital therapeutics have a future in medicine?

Wearables generate powerful data but its not useful to doctors, yet

A $475,000 price tag for a new cancer drug: crazy or meh?

Biden administration opens offers in Medicare drug price negotiations

explore

leisure time

leisure time

entertainment